VolitionRX (VNRX) Expected to Post Quarterly Earnings on Thursday

VolitionRX (NYSEAMERICAN:VNRX) is projected to issue its Q2 2026 results after the market closes on Thursday, August 13th. Analysts expect VolitionRX to post earnings of ($0.70) per share and revenue of $0.4150 million for the quarter. Investors may visit the the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Friday, August 21, 2026 at 8:30 AM ET.

VolitionRX (NYSEAMERICAN:VNRX) last issued its quarterly earnings data on Thursday, May 14th. The medical research company reported ($0.97) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.70) by ($0.27). The company had revenue of $0.99 million for the quarter, compared to the consensus estimate of $1.52 million.

VolitionRX Trading Down 1.1%

NYSEAMERICAN:VNRX opened at $0.77 on Tuesday. VolitionRX has a 12 month low of $0.69 and a 12 month high of $15.10. The company has a market cap of $6.62 million, a PE ratio of -0.18 and a beta of 1.16. The company has a 50 day simple moving average of $1.25 and a two-hundred day simple moving average of $2.86.

Analysts Set New Price Targets

VNRX has been the topic of a number of research reports. Citigroup downgraded VolitionRX to a “hold” rating in a research note on Monday, April 20th. Benchmark reiterated a “hold” rating on shares of VolitionRX in a research report on Tuesday, June 2nd. D. Boral Capital reiterated a “hold” rating on shares of VolitionRX in a research report on Monday, April 20th. Finally, Maxim Group reissued a “buy” rating and issued a $4.00 target price on shares of VolitionRX in a report on Thursday, June 18th. Two equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $28.00.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of VNRX. Virtu Financial LLC increased its stake in VolitionRX by 166.6% in the 4th quarter. Virtu Financial LLC now owns 108,581 shares of the medical research company’s stock worth $28,000 after buying an additional 67,848 shares in the last quarter. Squarepoint Ops LLC purchased a new position in shares of VolitionRX in the fourth quarter valued at about $34,000. Jane Street Group LLC bought a new position in shares of VolitionRX in the fourth quarter worth about $28,000. Geode Capital Management LLC boosted its stake in shares of VolitionRX by 9.8% in the fourth quarter. Geode Capital Management LLC now owns 963,986 shares of the medical research company’s stock worth $246,000 after acquiring an additional 85,816 shares during the period. Finally, Armistice Capital LLC grew its position in shares of VolitionRX by 10.4% during the third quarter. Armistice Capital LLC now owns 9,380,425 shares of the medical research company’s stock worth $6,367,000 after purchasing an additional 887,351 shares in the last quarter. Institutional investors own 8.09% of the company’s stock.

About VolitionRX

VolitionRX, traded as VNRX on the NYSE American exchange, is a pioneering life sciences company focused on the development and commercialization of minimally invasive diagnostic tests for the early detection of cancer and other diseases. Utilizing proprietary technology to analyze circulating nucleosomes in blood samples, the company’s platform identifies disease-specific epigenetic and biochemical signatures. By offering blood-based screening solutions, VolitionRX aims to deliver alternatives to invasive, costly and time-consuming procedures, potentially improving patient outcomes through earlier diagnosis.

The company’s flagship product suite, branded as Nu.Q, comprises assays designed to detect biomarkers associated with a range of malignancies, including colorectal, lung and pancreatic cancers, as well as other systemic conditions.